Payment overview · 2025
General Payments
$942.16
53 reported records · 24 companies
Healthcare provider profile · identity verified
George Steven Bailes, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARTANBURG, SC · NPI 1417935339
Verified facts
What the public records show
CMS Open Payments records show George Steven Bailes, MD received $942.16 in general payments during 2025 across 53 reported records.
PFIZER INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.16 | 17.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.33 | 15.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.85 | 10.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.08 | 5.8% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $48.55 | 5.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.92 | 4.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.74 | 3.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.84 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.17 | 3.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.90 | 3.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.32 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.67 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.38 | 2.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $22.17 | 2.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.58 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.00 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.07 | 2.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.07 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.17 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.13 | 1.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.57 | 1.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.29 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.92 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $942.16 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $118.64 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.85 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.50 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $71.32 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.60 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.60 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.88 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.13 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $48.55 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.52 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.52 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 597 | 157 |
| Omeprazole | Omeprazole | 377 | 109 |
| Lorazepam | Lorazepam | 369 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 80 |
| Simvastatin | Simvastatin | 258 | 73 |
| Metformin Hcl | Metformin Hcl | 256 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 77 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 223 | 44 |
| Lisinopril | Lisinopril | 210 | 60 |
| Furosemide | Furosemide | 207 | 62 |
| Meloxicam | Meloxicam | 206 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 188 | 137 |
| Tramadol Hcl | Tramadol Hcl | 179 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 164 | 48 |
| Alprazolam | Alprazolam | 158 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 143 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 37 |
| Sertraline Hcl | Sertraline Hcl | 137 | 38 |
| Benazepril Hcl | Benazepril Hcl | 136 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 39 |
| Alendronate Sodium | Alendronate Sodium | 131 | 37 |
| Valsartan | Valsartan | 127 | 30 |
| Temazepam | Temazepam | 122 | 23 |
| Celecoxib | Celecoxib | 118 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 109 | 26 |
| Allopurinol | Allopurinol | 104 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 30 |
| Gabapentin | Gabapentin | 101 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 29 |
| Atenolol | Atenolol | 99 | 29 |
| Glipizide | Glipizide | 94 | 28 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 91 | 20 |
| Carvedilol | Carvedilol | 89 | 25 |
| Pregabalin | Pregabalin | 88 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 25 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 86 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 23 |
| Clonazepam | Clonazepam | 83 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 19 |
| Potassium Chloride | Potassium Chloride | 81 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 65 |
| Nabumetone | Nabumetone | 79 | 16 |
| Eliquis | Apixaban | 77 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 18 |
| Azithromycin | Azithromycin | 72 | 63 |
| Clonidine Hcl | Clonidine Hcl | 69 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 16 |
| Prednisone | Prednisone | 63 | 47 |
| Trazodone Hcl | Trazodone Hcl | 63 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 19 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Ozempic | Semaglutide | 61 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 58 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 23 |
| Warfarin Sodium | Warfarin Sodium | 54 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 12 |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Glipizide Er | Glipizide | 49 | 16 |
| Losartan Potassium | Losartan Potassium | 49 | 17 |
| Lovastatin | Lovastatin | 49 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Levofloxacin | Levofloxacin | 43 | 37 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 13 |
| Gemfibrozil | Gemfibrozil | 41 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Valacyclovir | Valacyclovir Hcl | 41 | 17 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 27 |
| Ibuprofen | Ibuprofen | 36 | 11 |
| Spironolactone | Spironolactone | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | 11 |
| Famotidine | Famotidine | 31 | 11 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 14 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | 14 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $942.16 · 53 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, Leqembi, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, Rybelsus, Symbravo, TONMYA, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, XYOSTED, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error